HomeNewsPharmaceutical giant

Pharmaceutical Giant

Jump to

See EBITDA margins at 25% over 10 years: Glenmark CMD

The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.
India ignored warnings on foreign investor tax row: Sources

The Finance Ministry could have sidestepped a damaging multibillion-dollar tax row with foreign investors if it had acted on regular warning letters that officials had been sending since as long ago as September.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Pharmaceutical Giant

See EBITDA margins at 25% over 10 years: Glenmark CMD

India ignored warnings on foreign investor tax row: Sources